Wainwright Initiates Monte Rosa With a Buy as MRT-8102 Phase 1 Data Arrive Wainwright cites a $565M enterprise value, cash into 2029, and multiple trials. Credit: Monte Rosa Therapeutics Subscribe now Already have an account? Sign in.
